These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 31285178)
1. Durable Response After 2 Doses of Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer With an Isolated Brain Metastasis. Uprety D; Arjyal L; Vallatharasu Y; Bista A; Wittchow RJ; Marinier DE Clin Lung Cancer; 2019 Sep; 20(5):e552-e554. PubMed ID: 31285178 [No Abstract] [Full Text] [Related]
2. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Goldberg SB; Gettinger SN; Mahajan A; Chiang AC; Herbst RS; Sznol M; Tsiouris AJ; Cohen J; Vortmeyer A; Jilaveanu L; Yu J; Hegde U; Speaker S; Madura M; Ralabate A; Rivera A; Rowen E; Gerrish H; Yao X; Chiang V; Kluger HM Lancet Oncol; 2016 Jul; 17(7):976-983. PubMed ID: 27267608 [TBL] [Abstract][Full Text] [Related]
3. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. Peng TR; Tsai FP; Wu TW Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108 [TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma. Sukrithan V; Sandler J; Gucalp R; Gralla R; Halmos B Clin Lung Cancer; 2019 May; 20(3):e242-e246. PubMed ID: 30665873 [No Abstract] [Full Text] [Related]
5. Pembrolizumab for the treatment of non-small cell lung cancer. Lim SH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Expert Opin Biol Ther; 2016; 16(3):397-406. PubMed ID: 26800463 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. Georgieva M; da Silveira Nogueira Lima JP; Aguiar P; de Lima Lopes G; Haaland B Lung Cancer; 2018 Oct; 124():248-254. PubMed ID: 30268469 [TBL] [Abstract][Full Text] [Related]
7. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer. Varkaris A; Sehgal K; Rangachari D; Costa DB J Thorac Oncol; 2019 Feb; 14(2):e34-e36. PubMed ID: 30683297 [No Abstract] [Full Text] [Related]
8. Pembrolizumab Shows Promise for NSCLC. Cancer Discov; 2015 Jun; 5(6):572. PubMed ID: 25895920 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial. Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714 [TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Gubens MA; Sequist LV; Stevenson JP; Powell SF; Villaruz LC; Gadgeel SM; Langer CJ; Patnaik A; Borghaei H; Jalal SI; Fiore J; Saraf S; Raftopoulos H; Gandhi L Lung Cancer; 2019 Apr; 130():59-66. PubMed ID: 30885353 [TBL] [Abstract][Full Text] [Related]
13. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. Leventakos K; Mansfield AS BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930 [TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676 [TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Dang TO; Ogunniyi A; Barbee MS; Drilon A Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948 [TBL] [Abstract][Full Text] [Related]
16. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy: pembrolizumab-is the writing on the wall for cancer? Hutchinson L Nat Rev Clin Oncol; 2015 Jul; 12(7):371. PubMed ID: 25963092 [No Abstract] [Full Text] [Related]
18. Pembrolizumab Outperforms Docetaxel for NSCLC. Leslie M Cancer Discov; 2016 Mar; 6(3):223. PubMed ID: 26811324 [No Abstract] [Full Text] [Related]
19. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer. Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685 [No Abstract] [Full Text] [Related]
20. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis. Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]